Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia

EHA Congress 2022

9 - 12 Jun 2022

Published: 13 Jun 2022

Views: 48

Rating:

Save

Dr Harry Erba - The Duke Cancer Institue, Durham, USA

Dr Harry Erba presents data from the the QuANTUM-First international, randomised, double-blind, placebo-controlled phase 3 study during a press conference at the EHA 2022 meeting.

The study sought to determine whether the addition of quizartinib to standard induction and post-remission consolidation therapy followed by single-agent continuation of quizartinib for up to three years improved overall survival in patients with newly diagnosed FLT3-ITD positive AML.

Watch our interview with Dr Erba here

Read the news story here

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

Ponatinib superior to imatinib in combination with reduced-intensity...

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

More from ecancer